C-11 MRB PET imaging of the brain's norepinephrine system in people with MS
Official title: Molecular Imaging of Norepinephrine Transporter (NET) Using [C-11]Methylreboxetine PET in Multiple Sclerosis
Run by Brigham and Women's Hospital · NCT03207464 · Data updated 2026-11-12
This project will try C-11 MRB PET scans to see if the brain's norepinephrine transporter is lower in adults with multiple sclerosis than in similar healthy adults.
Quick facts
| Phase | Phase1; Phase2 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years to 60 Years |
| Sex | All |
| Enrollment | 19 (estimated) |
| Sponsor | Brigham and Women's Hospital Academic / other |
| Drugs / interventions | radiation |
| Locations | 1 site (Boston, Massachusetts) |
| Status | Recruiting |
| Started | October 10, 2017 |
| Main results expected | December 31, 2026 |
| Study ends | December 31, 2026 |
| Registry record updated | February 2, 2026 |
| Trial ID | NCT03207464 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults 18–70 years old who meet the international criteria for MS with EDSS under 7.5, who can safely undergo PET and MRI, are not pregnant or nursing, and are not taking excluded antidepressant medications would be ideal candidates.
✕Probably not a fit
People who are pregnant or nursing, cannot undergo MRI/PET (for example due to incompatible implants or severe claustrophobia), are taking excluded norepinephrine-active drugs, or expect direct therapeutic benefit are unlikely to gain clinical benefit from participation.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This interventional imaging study uses the radioligand C-11 MRB with PET to measure norepinephrine transporter (NET) binding in the brains of people with multiple sclerosis (MS) and age- and sex-matched healthy controls. The protocol plans to enroll 12 participants (about 8 with MS and 4 healthy controls), all aged 18–70 with MS patients having EDSS below 7.5, who will undergo MRI and a roughly 120-minute PET scan. Researchers will compare NET binding between groups and correlate binding measures with clinical severity and MRI parameters. The radiotracer dose is low and not expected to cause pharmacologic effects, but participants will have small radiation exposure and must meet safety and medication exclusion criteria.
Why it matters
Potential benefit: If successful, the approach could provide a new biomarker to detect noradrenergic system injury in MS and help link those changes to clinical severity.
How similar studies have gone: C-11 MRB PET has been used to image NET in other neurologic and psychiatric conditions, but applying it specifically to MS is relatively novel and supported only by limited prior data.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Individuals meeting the definition for Multiple Sclerosis by the International Panel Criteria, with an Expanded Disability Status Scale (EDSS) less than 7.5 2. Male and female subjects age 18 to 70 years 3. Subjects willing to undergo PET and MRI imaging 4. Subjects willing and able to give informed consent Exclusion Criteria: 1. Individuals with a comorbid severe psychiatric condition such as schizophrenia, bipolar disorder, or post-traumatic stress disorder. 2. Individuals with a known alternate neurologic disorder, previous head injury, or substance abuse. 3. Individuals taking tricyclic antidepressants, serotonin-norepinephrine reuptake inhibitors, or norepinephrine-dopamine reuptake inhibitors. 4. Concurrent medical conditions that contraindicate study procedures. 5. Women who are pregnant or nursing. Also, any woman who is seeking to become pregnant or suspects she is pregnant will be excluded from enrollment. 6. Claustrophobia 7. Non-MRI compatible implanted devices 8. Corticosteroid treatment in the past four weeks
Where it's running
-
Brigham MS Center, 60 Fenwood Road
Boston, Massachusetts, United States Recruiting
Study contacts
- Principal investigator: Tarun Singhal, M.D. — Brigham and Women's Hospital
- Study coordinator: Tarun Singhal, M.D.
- Email: tsinghal@bwh.harvard.edu
- Phone: 617-264-3043
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Treadmill-based virtual reality walking training for MS patients
This study tests whether a treadmill with virtual reality and smart socks can help people with multiple sclerosis walk better and feel safer in daily life.
-
Virtual Reality and Mental Practice to Improve Balance and Walking in Relapsing MS
This study tests whether virtual reality training or mental practice can improve balance and walking in people with relapsing–remitting multiple sclerosis.
-
REAL-MS: A Look at Autologous Stem Cell Transplant vs High-Efficacy MS Therapies in Real-World Care
This study tests how AHSCT compares to high-efficacy MS medicines in adults treated in routine clinical care.
-
Tolebrutinib in real-world MS care for patients treated by clinicians
This real-world study sees how tolebrutinib is used for multiple sclerosis patients and what outcomes look like in everyday practice.
-
Pilates via live video vs. prerecorded videos for people with multiple sclerosis
This study tests whether live, coach-led Pilates sessions through video calls are more beneficial than prerecorded Pilates videos for adults with MS.
-
Cooling During Inpatient Rehab for People with MS
This trial tests whether wearing a cooling vest during intensive training can reduce fatigue and improve walking, strength, balance, and cognition in people with multiple sclerosis during a 3-week inpatient rehab stay.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.